David Planchard: First patient included in the INDIGO study
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared a post on LinkedIn:
“First patient included in the INDIGO study!
We’re proud to announce the launch at Gustave Roussy of the INDIGO clinical trial, with the first patient now enrolled.
This groundbreaking randomized phase II study is the first to investigate a chemotherapy-free first-line regimen for patients with advanced non-small cell lung cancer (NSCLC) selected based on the presence of tertiary lymphoid structures (TLS) in their tumors.
Why is this important?
- TLS have emerged as the most powerful predictor of response to immunotherapy, independently of PD-L1 status.
- INDIGO leverages this biology to explore the combination of tiragolumab + atezolizumab vs atzeolizumab alone in TLS+ NSCLC patients (PDL1 <50%)
- This trial could pave the way for precision immunotherapy, sparing patients from unnecessary chemotherapy.
A big thank you to all collaborators and teams involved in making this happen – this is a major step forward for science and patients.”
More posts featuring David Planchard.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023